This clinical research explores the integration of multiple biological data types—genomics, proteomics, metabolomics—with continuous biosensing to enable truly personalized medicine. By combining diverse biological data sources, we can identify individual-specific health patterns and treatment responses.
Traditional medicine treats patients based on diagnosis rather than individual biology. This study investigates how integrating genomic, proteomic, and metabolomic data with continuous biosensing can enable personalized treatment approaches for chronic conditions.
We enrolled 200 patients with mast cell activation syndrome and related conditions. Participants underwent comprehensive omics analysis (whole genome sequencing, serum proteomics, urinary metabolomics) alongside continuous biosensing for 8 weeks. We used machine learning to identify individual-specific patterns.
Our integrated analysis identified distinct patient subgroups based on combined omics profiles, each showing unique biosensing patterns and treatment responses. Patients with specific genetic variants showed predictable metabolomic signatures that correlated with disease severity.
Importantly, personalized predictions based on omics data plus real-time biosensing achieved 89% accuracy in predicting individual symptom episodes, compared to 62% with biosensing alone.
These findings support the development of personalized medicine approaches where individual omics profiles guide treatment selection and monitoring strategies.
Multi-omics integration with continuous monitoring enables true precision medicine tailored to individual biology.